An older person living with diabetes, hypertension, heart disease and chronic pain may receive medicines from several professionals, purchase additional products without a prescription and rely on a relative to organize tablets at home. Each treatment may have begun for a legitimate reason. The risk emerges when nobody has a reliable view of the whole medication regimen, how the person actually takes it or whether one medicine is now contributing to dizziness, confusion, falls or functional decline.
This makes medication management an important part of the wider Mexico Aging, Long-Term Care & Community Support Knowledge Hub. As Mexico's population ages and more people live for longer with multiple chronic conditions, the question is no longer simply whether effective medicines are available. It is whether prescribing, dispensing, monitoring and everyday use remain coordinated around the person.
Mexico already has substantial clinical expertise in geriatric pharmacotherapy. The Instituto Nacional de Geriatría, INGER, includes chronic medication use, polypharmacy and pharmacoepidemiology within its research agenda, while the Instituto Nacional de las Personas Adultas Mayores, INAPAM, has recently emphasized the risks associated with polypharmacy, self-medication and prescribing cascades. The operational challenge is translating these principles consistently across a health system in which older people may move between different institutions, specialists, pharmacies, hospitals, home-based services and family support.
Medication safety therefore depends on much more than accurate prescribing. It requires reconciliation, review, communication, adherence support, monitoring and clear responsibility when circumstances change.
Polypharmacy is not simply a problem of taking many medicines
Polypharmacy is often described numerically, but the number of medicines alone does not determine whether treatment is appropriate.
An older person with several well-managed chronic conditions may legitimately require multiple medicines. Conversely, a person taking fewer medicines may still face significant risk if one is inappropriate, duplicated, interacting with another treatment or being taken incorrectly.
The more useful distinction is between necessary multidrug treatment and medication burden that is no longer optimized around the person's current health, function and goals.
INAPAM reported in January 2026 that ENSANUT 2018–19 data showed a polypharmacy prevalence of 26.5% among older people and emphasized its association with chronic degenerative conditions including hypertension, diabetes and heart disease. It also highlighted self-medication and unsupervised use of products such as analgesics and benzodiazepines as additional sources of risk.
These issues place medication management within the wider challenge of medication management and polypharmacy.
The central policy question should therefore not be how to minimize medication at all costs. It should be how to ensure that every medicine continues to have a valid purpose, remains appropriate for the individual and is monitored in the context of everything else the person is taking.
Mexico's chronic-disease burden makes medication coordination increasingly important
Medication complexity is closely connected to multimorbidity. Older people may simultaneously require treatment for hypertension, diabetes, cardiovascular disease, respiratory conditions, pain, osteoporosis, depression, sleep problems or other long-term conditions.
Different conditions may be managed by different parts of Mexico's health system. An older person may receive primary and specialist care through IMSS, ISSSTE, IMSS-Bienestar or another public institution depending on entitlement and circumstances, while private consultations and pharmacies may also form part of the person's real care pathway.
This institutional diversity matters because medication risk often occurs at the interfaces.
A specialist may adjust one medicine without immediately seeing another prescriber's change. A hospital may alter treatment during admission. A person may continue tablets that were intended to be stopped. A relative may purchase a familiar product after the prescription has changed. Herbal remedies, supplements and over-the-counter medicines may not appear on the clinical medication list at all.
Medication safety is therefore inseparable from long-term conditions and chronic disease management.
The stronger approach is to treat the medication regimen as one integrated therapeutic plan rather than as a collection of separate prescriptions attached to separate diagnoses.
Medication review needs to ask whether treatment still fits the person
A medication review should do more than confirm that prescriptions remain active.
INGER guidance on pharmacological evaluation for older people has emphasized establishing a complete medication list, confirming the clinical indication for each medicine, identifying potentially inappropriate medicines and relevant interactions, avoiding prescribing cascades, assessing adherence and ensuring doses reflect individual factors such as renal function.
That creates a different conversation from simply renewing prescriptions.
The review needs to consider whether the medicine is producing the intended benefit, whether adverse effects have appeared, whether the person's health has changed and whether the treatment remains consistent with current priorities.
Important questions include:
- Does every medicine still have a clear clinical indication?
- Are two medicines unintentionally treating the same problem?
- Could a new symptom represent an adverse effect rather than a new disease?
- Has renal, hepatic, cognitive or functional change altered medication risk?
- Can the person realistically manage the dosing schedule?
- Are non-prescription products or supplements changing the risk profile?
This is particularly important where treatment has accumulated over years. Medicines can remain on a list long after the original clinical circumstances have changed.
Deprescribing may sometimes be appropriate, but it should itself be a clinical process. Abrupt withdrawal can create harm. The objective is optimized treatment, not an arbitrary reduction in tablet numbers.
Operational scenario: a prescribing cascade looks like deteriorating health
A 78-year-old man with hypertension, diabetes and osteoarthritis begins experiencing dizziness and increasing unsteadiness. His daughter also notices that he appears sleepier during the afternoon.
He has recently received an additional medicine after reporting difficulty sleeping. At another consultation, treatment was adjusted because his blood pressure appeared poorly controlled. He also uses an over-the-counter analgesic regularly but has never considered it a "medicine" worth mentioning.
If each symptom is assessed independently, further prescriptions could be added. Instead, the primary care review reconstructs the complete medication history, including non-prescription use and recent changes.
The clinician considers whether medication effects or interactions could be contributing to the dizziness and sedation, reviews the indication and timing of the treatments and reassesses his blood pressure in context. His daughter is involved because she helps organize his medicines, but the man remains central to decisions about his treatment.
The outcome is not simply fewer medicines. It is a clearer regimen, better understanding of what each medicine is for and a plan for monitoring symptoms after changes.
For organizations examining comparable high-risk medication pathways, the Quality Improvement Action Plan Builder can help translate recurring medication problems into structured improvement actions, ownership and follow-up without replacing clinical judgment or Mexican prescribing guidance.
Transitions between services are high-risk medication moments
Hospital admission and discharge can substantially alter an older person's medication regimen.
A medicine may be temporarily withheld during acute illness. A new treatment may be started. Doses may change. Medicines may be stopped because of adverse effects or changed clinical priorities.
The danger arises when the revised regimen does not travel clearly with the person.
At home, an older person may have boxes of medicines from before admission alongside a new discharge prescription. A family member may reasonably assume that all of them should continue. The next clinician may not immediately know which changes were temporary and which were intended to be permanent.
This makes medication reconciliation an essential part of hospital discharge and transitional care.
A robust transition establishes what the person was taking before admission, what changed during treatment, what should be taken now, why changes were made and who will review the regimen next.
For older people with cognitive impairment, limited health literacy or substantial treatment complexity, written information alone may be insufficient. Communication needs to reflect who actually manages medicines once the person returns home.
Operational scenario: two medication lists arrive home after hospital discharge
An 82-year-old woman with heart failure and diabetes returns home after a hospital admission. Her daughter collects the discharge medicines and notices that several tablets look different from those already stored in the kitchen.
The family has the hospital instructions, an older primary care prescription and boxes from before admission. They are uncertain whether one blood-pressure medicine was stopped or merely omitted from the new supply.
The safest response is not to expect the daughter to reconstruct the clinical decision herself.
Medication reconciliation compares the pre-admission regimen with the discharge list and confirms the intended changes. The reason for each significant change is explained, duplicate supplies are identified and follow-up is arranged for medicines requiring monitoring.
The process also discovers that the woman has been taking an anti-inflammatory medicine purchased independently for knee pain. Because it was not included in the original hospital medication history, its continued use needs clinical consideration alongside her cardiovascular treatment.
The scenario illustrates why medication safety is a pathway responsibility rather than simply a prescribing responsibility. The quality of the discharge prescription matters, but so does whether the person, family and next clinical team understand it.
Organizations assessing comparable coordination arrangements can use the Governance Maturity Assessment to examine whether responsibility, escalation and information flow are sufficiently clear across service interfaces.
Self-medication changes the real medication picture
Formal prescription records do not necessarily show everything an older person takes.
Mexico has extensive community pharmacy access, and medicines or health products may also be obtained outside the clinical pathway. INAPAM has specifically warned about self-medication among older people, including the recurrent use of analgesics and benzodiazepines without adequate professional oversight.
Supplements, herbal preparations and remedies recommended by relatives or friends may also form part of an individual's health practices.
The appropriate response is not to dismiss these choices or assume that people deliberately conceal information. Someone may simply not regard an over-the-counter product, tea, supplement or medicine used only occasionally as relevant to the clinician.
Medication assessment therefore needs culturally respectful questioning about what the person actually uses rather than only what appears on a prescription list.
The distinction matters because interactions do not depend on whether a product came from a formal prescription. Neither does treatment burden.
Pharmacists can play an important role in identifying duplication, unusual combinations or difficulties with adherence, particularly because pharmacies may be more accessible than specialist services. The effectiveness of that role depends on communication pathways and the scope of the particular service rather than assuming that every community pharmacy has access to the person's full clinical record.
Adherence is often a system-design issue rather than patient non-compliance
Medication adherence can be discussed as though the older person either follows instructions or fails to do so. That framing misses much of the operational reality.
A person may be expected to take tablets at several different times of day, with different relationships to food, while also monitoring glucose or blood pressure. Packaging may be difficult to open. Labels may be hard to read. Cognitive impairment may make it difficult to remember whether a dose has already been taken.
Financial or supply difficulties can also affect continuity. A medicine that is theoretically prescribed is not therapeutically effective if the person cannot obtain it consistently.
Safer medication systems therefore need to understand why doses are missed, duplicated or deliberately altered.
The response may involve simplifying a regimen where clinically possible, clearer explanation, accessible labeling, adherence aids, family support, synchronized supply or closer follow-up.
Where family members help, their involvement should be visible rather than assumed. This connects medication safety with caregiver supports, respite and family navigation.
A daughter who organizes eight medicines every week is performing a significant care task. She needs accurate information and a route for raising concerns. She should not, however, be expected to make clinical decisions about dose changes because professional coordination is weak.
Cognitive change creates additional medication risks
Medication management becomes particularly complex when an older person develops memory difficulties or dementia.
Someone may forget a dose, take it twice or struggle to understand a recently changed regimen. At the same time, cognitive impairment does not automatically mean that the person should lose all involvement in medication decisions.
The level of support should reflect the individual's actual abilities and preferences.
Simple measures may preserve independence: clearer routines, organized dispensing systems, visual prompts or supervised preparation with the person continuing to take medicines independently.
Where risks increase, support can become more intensive. The objective is proportionate assistance rather than immediately transferring total control to a family member.
This connects medication practice with rights, consent and decision-making. People should receive explanations in a form they can understand and remain involved in choices for as long as possible.
Medication can also affect cognition. New confusion should not automatically be interpreted as irreversible deterioration. Adverse effects, interactions, infection and other acute conditions may require assessment.
Home-based care can make medication reality more visible
Clinical consultations show the prescribed regimen. Home visits can reveal how that regimen actually operates.
A health worker may see unopened boxes, duplicate medicines, several prescribing instructions, tablets stored in different rooms or an older person unable to explain what a medicine is for.
Mexico's Salud Casa por Casa program creates a potentially important point of contact in this respect. Its home visits to older people and people with disabilities can bring health assessment closer to everyday living conditions. The program should not be treated as a comprehensive medication-management or long-term care service, but its home-based model creates opportunities to identify issues that warrant further clinical review.
The same principle applies to future expansion of home- and community-based services within Mexico's developing care architecture.
Workers entering people's homes may become the first to notice that a medication routine is no longer manageable. Clear role boundaries are essential. A care worker should not independently change prescribed treatment, but should know how to document and escalate concerns such as repeated missed doses, excessive sedation, dizziness or difficulty swallowing.
Operational scenario: the medication list is correct but the routine is not
A 74-year-old woman living in a semi-rural community has diabetes and hypertension. Her prescriptions are clinically current, and there is no obvious duplication on the medication list.
During a home visit, however, it becomes clear that she regularly misses an afternoon dose because she spends several hours away from home helping at a family business. She sometimes compensates by taking it later with another medicine.
She has not mentioned this during clinic appointments because she does not consider it a problem and does not want to be told to stop helping her family.
The issue is not solved by repeating the original instruction more firmly.
The clinician needs to understand her daily life and determine whether the regimen can safely be adjusted or simplified. The woman explains which routines matter to her, and any change remains a clinical decision made with her rather than around her.
The scenario demonstrates the difference between theoretical adherence and workable treatment. Medication plans need to fit the person's life sufficiently well to be sustainable.
It also highlights why person-centered medication management is not simply about preference. Understanding everyday routines can reveal practical safety risks that a prescription record cannot.
Medicine supply and access are part of medication safety
Medication governance cannot focus exclusively on inappropriate prescribing. Under-treatment and interrupted treatment can also cause harm.
For people with chronic disease, consistent access to essential medicines matters. Supply interruptions, geographic barriers or uncertainty about where a prescription can be filled may undermine disease control even when the clinical plan is appropriate.
Mexico is currently developing additional medication-access mechanisms around Salud Casa por Casa. Farmacias del Bienestar began operating initially in the State of Mexico in December 2025, with the federal government describing the model as a route for supplying medicines prescribed through the home-based program.
As such models develop, the important governance question is not simply how many medicines are distributed. It is whether prescribing, dispensing and follow-up remain connected.
Access without review can perpetuate inappropriate treatment; review without reliable access cannot produce the intended therapeutic outcome.
This makes medication availability part of a broader continuity system.
Digital medication information could reduce fragmentation
Medication safety depends heavily on information.
Ideally, clinicians reviewing an older person's treatment should be able to see a sufficiently current picture of prescribed medicines, significant recent changes, allergies and relevant monitoring. In practice, information may sit across institutional records, paper prescriptions, discharge documents, pharmacy systems and the person's own memory.
Mexico's movement toward more digital health information creates opportunities to improve continuity, but interoperability cannot be assumed simply because individual systems become electronic.
A digital medication list is useful only if it is current, accessible to appropriate professionals and updated when treatment changes. Poor-quality electronic information can create false confidence.
There are also legitimate privacy and consent questions. Medication information is sensitive health data, and broader sharing requires proportionate access controls and clear purposes.
This connects safer prescribing with interoperability and data exchange workflows.
Organizations exploring similar digital pathways can use the Digital Transformation, AI and Cybersecurity Readiness Assessment to examine whether information infrastructure, workforce readiness, privacy and governance are developing together rather than treating digitization as a purely technical project.
Rural and regional variation affects access to medication review
The risks associated with complex medication are not geographically uniform.
Older people in major urban centers may have greater access to geriatricians, specialist clinics and multidisciplinary review. INGER itself provides specialized outpatient geriatric assessment, while INAPAM's Centro de Atención Integral Universidad in Mexico City offers gerontological medical services including comprehensive assessment.
These specialist resources are valuable, but they cannot be the only route to safer medication management across a country of Mexico's scale.
Primary care therefore has a crucial role. Clinicians need practical support to recognize inappropriate prescribing, interactions, prescribing cascades and treatment burden among older people with multimorbidity.
Telehealth may extend specialist advice in some circumstances, particularly for medication review where appropriate clinical information is available. Digital tools may also support interaction checking and medication reconciliation.
However, technology cannot compensate for incomplete information or lack of clinical ownership.
Geographic equity should therefore be assessed through whether older people can obtain meaningful review and follow-up, not simply whether national geriatric expertise exists.
Medication safety depends on workforce competence across settings
Medication management involves a wider workforce than prescribers alone.
Doctors make prescribing decisions. Nurses monitor health and may identify adverse effects. Pharmacists contribute expertise on medicines and interactions. Rehabilitation professionals may notice dizziness or sedation affecting function. Home-care workers can observe changes in everyday behavior. Family caregivers frequently organize, collect and supervise medicines.
Each role sees a different part of the medication pathway.
The system becomes safer when people know what they are responsible for and when to escalate.
For formal care services, competence should include recognizing common medication risks, recording administration accurately where this forms part of the role, responding to missed doses through established procedures and reporting suspected adverse effects rather than independently altering treatment.
This makes staff competence and training assurance increasingly relevant as Mexico professionalizes its care workforce.
Medication support should form part of that professionalization because expansion of home and community care will inevitably bring more workers into contact with people managing complex treatment regimens.
Operational scenario: sedation in residential care should trigger review, not normalization
An older man living in a residential care setting becomes increasingly sleepy during the day and less steady when walking. Staff begin accompanying him more closely because they are concerned about falls.
The change could easily be attributed to aging or increasing frailty.
Instead, the service reviews when the change began and finds that it followed a medication adjustment made after several nights of agitation. The concern is escalated for clinical assessment rather than managed solely through additional supervision.
The clinician reviews the indication, timing, dose, other medicines and possible causes of the original agitation. Pain, sleep pattern, environmental disruption and other clinical explanations are considered rather than assuming that sedation is an unavoidable cost of controlling behavior.
The person's mobility and alertness improve after the treatment plan is clinically revised.
The scenario illustrates why medication effects need to be visible within quality governance. Increased falls, daytime sleepiness or sudden functional decline may be medication signals as well as care problems.
Where residential or community providers track these patterns, they can identify whether similar concerns recur across several people and whether prescribing review is occurring promptly.
Quality measurement should connect medication activity with outcomes
Medication governance can easily become focused on process: prescriptions completed, medicines administered and records signed.
Those controls matter, but they do not show whether treatment is producing safe and meaningful outcomes.
A stronger evidence framework could examine:
- completion of medication reconciliation after significant transitions;
- timely review of complex or high-risk medication regimens;
- suspected adverse drug events and resulting action;
- falls, confusion or functional decline potentially associated with medicines;
- avoidable duplication and unresolved discrepancies;
- people's understanding of their medicines where appropriate; and
- continuity of access to essential treatment.
These indicators need interpretation rather than simplistic targets. A higher number of medication reviews, for example, is not automatically evidence of better care if reviews do not lead to appropriate action.
The Quality Dashboard Builder can help organizations structure comparable medication-safety indicators around process, risk and outcomes while retaining the need for country-specific clinical interpretation.
Mexico's developing care system creates an opportunity for medication governance
Medication safety illustrates why health and long-term care cannot be designed as separate worlds.
As Mexico develops the Sistema Nacional y Progresivo de Cuidados, more formal support may be provided to older people who live with multimorbidity, disability, dementia or frailty. Those support arrangements will inevitably interact with medical treatment.
The care system does not need to become a parallel prescribing system. It does need reliable interfaces with health services.
A home-care worker observing repeated dizziness needs an escalation route. A residential service needs access to appropriate clinical review when medication concerns arise. A family caregiver needs clear information following treatment changes. Hospital discharge arrangements need to recognize who will actually support medication at home.
This is where care coordination across health and social care becomes operational rather than conceptual.
The developing care architecture also creates an opportunity to establish expectations before fragmented practices become embedded. Medication competence, escalation, information sharing and outcome monitoring can be designed into emerging service models rather than added later as corrective controls.
What Mexico's experience offers internationally
Mexico's medication challenge reflects several issues shared by aging societies, although its institutional structure, access arrangements and family-care patterns are distinct.
The first lesson is that polypharmacy should not be reduced to a medicine count. Appropriate multiple treatment may be essential; the real question is whether the regimen remains clinically justified, coordinated and manageable.
Second, medication reconciliation is particularly important at transitions. The risk is not confined to the prescribing decision but includes whether treatment changes are understood and implemented after the person moves between settings.
Third, self-medication and non-prescription products need to be incorporated into medication assessment without stigmatizing the person. The clinically relevant medication list is the list of what someone actually takes.
Fourth, adherence needs to be understood through everyday life. Complex routines, cognitive change, accessibility, supply and family support can all influence whether a technically correct treatment plan works in practice.
Finally, long-term care systems need medication interfaces even where prescribing remains firmly within the health system. Care workers and families frequently observe the effects of medicines between clinical encounters.
The transferable principle is therefore not a particular institutional mechanism. It is the need to govern the entire medication pathway around the person rather than assuming that safe individual prescriptions automatically create safe medication use.
Conclusion
Medicines will remain central to healthy aging in Mexico. As more people live longer with multiple chronic conditions, appropriate pharmacological treatment can prevent complications, control symptoms and support independence. The challenge is ensuring that the accumulation of treatment does not itself become a source of avoidable harm.
Mexico already has important foundations. INGER's geriatric work recognizes polypharmacy, medication assessment and functional health as interconnected issues, while INAPAM has brought renewed attention to self-medication, prescribing cascades and the need for periodic review. Home-based health initiatives and developing digital infrastructure create further opportunities to identify how medicines are actually being used outside clinical settings.
The stronger direction is a medication system built around continuity: complete medication histories, appropriate prescribing, reconciliation after transitions, meaningful review, reliable access, clear family support and rapid response when adverse effects or functional changes emerge. As the Sistema Nacional y Progresivo de Cuidados develops, those principles also need to reach home and community services without blurring clinical responsibilities.
Medication safety is ultimately not measured by how many tablets an older person takes. It is measured by whether treatment remains necessary, understandable, accessible and compatible with the person's health, function and goals. Connecting prescribing decisions with everyday experience will be essential if Mexico is to manage increasing clinical complexity while preserving autonomy and quality of life in later years.